

Title: Does earlier diagnosis and treatment of brain tumours matter? Time-to-treatment intervals and tumour size at detection; impact on survival and other patient outcomes

Authors: Ewan Gray^{1†}, James Cameron², Abigail Lishman², Peter Hall³, Piyumanga Karunaratne³, Giovanni Tramonti³, Maheva Vallet³, Luke Pike⁴ and Matthew Baker⁵, Paul M Brennan^{6‡}.

¹ Freelance Consultant, Edinburgh, UK; ² Dxcover Ltd, Glasgow, UK; ³ University of Edinburgh, Edinburgh, UK; ⁴ Memorial Sloan Kettering Cancer Center, New York, USA ⁵ Dxcover Ltd & School of Medicine & Dentistry, University of Lancashire, UK ⁶ University of Edinburgh & NHS Lothian, UK.

†Corresponding Authors. Ewan Gray, address: 21 Oswald Court, Edinburgh EH92HY, UK email: ewan@eghealththeconomics.com, telephone: 07837961652. Paul Brennan, address: Translational Neurosurgery, Centre for Clinical Brain Sciences, University of Edinburgh, Edinburgh EH4 2XU, UK. E-mail: paul.brennan@ed.ac.uk, telephone: 0131 650 1000

Abstract

Background: The importance of timely diagnosis of brain tumours is well recognised but how this translates to impact on important patient outcomes is not well described. This observational study aimed to quantify the effect of time-to-treatment interval and tumour size at diagnosis on six patient outcomes: tumour-specific survival, overall survival, new or worsened neurological deficit, 30-day mortality, recurrence and inpatient length of stay.

Methods: A retrospective cohort study including 1196 patients from Southeast Scotland diagnosed with brain tumours between 2010 and 2020. Analysis was stratified by tumour type in three categories: Glioblastoma (GBM) and other grade 4 brain tumours, grade 1-3 tumours and brain metastases. Regression methods (Cox, Logistic & Linear) were used to estimate per day impact of time-to treatment and tumour size impact on outcomes.

Results: The mean time from first presentation to treatment was 161 days (median: 57 days). Time-to-treatment results showed an association between longer intervals and reduced mortality. The mean tumour size was 4.06cm (SD: 1.75cm). For GBM and grade 4 tumours, each 1cm increase in tumour size increased tumour-specific mortality risk by approximately 11% (HR: 1.11, 95%CI: 1.05-1.16) and increased all-cause mortality by 10% (HR: 1.10, 1.05-1.16). Associations between tumour size and the outcomes of brain tumour mortality, all-cause mortality and inpatient length of stay were consistent across tumour subgroups.

Conclusions: Larger tumour size was consistently associated with increased hazard ratios for mortality. Applying these estimates together with estimates of mean tumour growth rates available in the literature, if a 6cm Glioblastoma tumour were diagnosed 3 months earlier then we would expect a 17-26% reduction in hazard of brain tumour mortality.

Importance of the Study: These findings reinforce the potential positive impact of earlier diagnosis for brain tumour patients. Building upon the accumulated evidence that tumour size is a critical factor influencing prognosis, this study is the first to focus on estimating causal associations with patient outcomes. Earlier detection, through influence on tumour size at diagnosis, may offer measurable survival benefits and potential reductions in healthcare resource use. There are limitations of an observational study design, but we believe our large, robust dataset and detailed analysis provide a stronger foundation for advocating further prospective research such as trials or pilots of early diagnostic interventions.

Keywords: Brain tumour, early diagnosis, tumour size

Key points:

1. Larger tumour size was associated with increased mortality.
2. Longer time-to-treatment interval was associated with reduced mortality, evidence of the 'waiting time paradox'.

Introduction

Diagnosis of brain tumours suffers from two related problems, an excess of emergency presentations (1) and long diagnostic intervals(2). NHS England route-to-diagnosis data show that approximately 40% of primary brain cancers present as an emergency each year (1). In the UK, most (80%) brain tumour patients report one or more primary care visit in the months preceding diagnosis (3), and more than a third of patients have 3 or more primary care visits recorded (4). These data suggest opportunities for earlier diagnosis (5).

Despite the potential for earlier diagnosis, interventions aiming to improve speed and accuracy of diagnosis face barriers in demonstrating their impact and value. While the importance of a timely diagnosis is recognised by professionals and policy makers, how this translates in a quantitative sense to important patient outcomes such as survival, quality of life and length of hospital stays, is not well described. Consequently, the impact of earlier diagnoses on population health and healthcare resource use are highly uncertain. This creates difficulty for the economic evaluation of interventions aiming to aid earlier brain tumour diagnosis (6,7). Evidence from real world observational data can help address this.

The Edinburgh brain tumour database utilised by this study is well suited to interrogate the relationship between time to diagnosis and patient outcomes. This manually curated data was collected specifically to understand clinical pathways for brain tumour patients and can be supplemented through linkage to routine healthcare records.

Prior studies in this area have explored only limited aspects of the relationship between earlier (or delayed) diagnosis, treatment, and patient outcomes. The overall pattern of findings reveals inconsistency, with positive (longer times associated with improved outcome) (8), negative (9,10) and null (11) associations identified. An important part of the explanation of these seemingly contradictory findings is the 'waiting time paradox' (12–14), the phenomenon where a delayed diagnosis or treatment can paradoxically mean a better prognosis for the patient. This is due to differences between cases in clinical features that may induce delay and are also associated with better outcomes. For example, a longer diagnostic process is more likely for less severely impairing symptoms, and such symptoms may be more commonly associated with less aggressive disease.

To better elucidate the relationship between earlier or delayed diagnosis and patient outcomes, this study investigated two associations. Firstly, the association between time-to-treatment and outcomes. Secondly, the association between tumour size and outcomes.

Tumour size is expected to mediate the impact of earlier or delayed diagnosis through the process of tumour growth. Pre-operative tumour size is a well-defined prognostic factor for both low- and high-grade brain tumours (15–19). Larger tumour size can increase the risk of both neurological deficits at presentation and surgical complications following resection.

While the relationship between tumour size and patient outcomes is well described in the literature, this study examines it from a unique perspective. Prior studies were concerned with the prognostic (predictive) value of tumour size rather than trying to estimate a causal effect (20). The multivariate analysis reported in these studies are inappropriate from a causal perspective due to including potential confounders such as tumour growth rate (21), mediators of the effect of tumour size such as extent of resection(16,17), or potential outcomes of tumour size (colliders) such as pre-operative symptoms (17,18). The reported results are therefore potentially biased estimates of the causal effect of tumour size on patient outcomes.

Patient outcome variables were selected based on known clinical relevance and availability in the database. The main objectives of the study were specified as estimation of the association between the two indicators of earlier or later diagnosis, i) tumour size and ii) length of the presentation to treatment interval, with the patient outcomes of brain tumour specific survival and overall survival. Additional objectives were to estimate the association of these indicators with the patient outcomes of new or worsened neurological deficit, 30-day mortality, cancer recurrence and inpatient length of stay in 12 months following diagnosis.

Methods

Study design: A retrospective cohort study.

Patient data: All patients were identified from the Edinburgh brain tumour database, which includes consecutive patients whose care was discussed at the institutional neuro-oncology multi-disciplinary meeting. Patients diagnosed with brain tumours between 1st January 2010 to 31st May 2020 were included in the study. Follow up was available until 31st May 2021 for all patients.

Brain tumour diagnosis was defined as a radiological diagnosis with or without recorded pathology diagnosis. Brain tumour types were defined based on diagnosis labels manually recorded from the radiology report. Inclusion criteria limited the study to patients aged 18 and over. Exclusion criteria of previous history of other cancer within the last 3 years was applied.

Data processing: Patient information was collected from manually curated fields compiled in the database and supplemented by data-linkage with national routine datasets (SMR00 - Outpatient, SMR01- Inpatient and SMR06 – Cancer Registry). Pseudonymous data linkage was achieved by linking the patient's database id number to their NHS Scotland Community Health Index (CHI) number. Data processing was completed within an NHS IT environment by an NHS analyst.

Tumour size was defined as the largest diameter of the tumour given in the diagnostic report (CT or MRI). Time-to-treatment interval was defined in two ways, [1] as time from first presentation to first recorded treatment (any one of surgery (including biopsy), radiotherapy or Temozolomide). This is equivalent to the primary care interval plus the secondary care interval(22), and [2] in sensitivity analysis only time from radiological diagnosis to first recorded treatment (the treatment interval only(22)). Time of first presentation was defined as the date of first recorded clinical appearance or the first date of recorded symptoms if this was earlier. Date of diagnosis refers to the date of the first imaging procedure that confirmed a radiological diagnosis. The date of treatment is the date first treatment was received, whether this was surgery, radiotherapy or chemotherapy.

Outcome variables included all-cause mortality, brain tumour specific mortality (Supplementary Appendix reports ICD-10 codes included for this outcome), 30-day (all-cause) mortality, new or worsened neurological deficit, tumour recurrence (confirmed radiologically), and total inpatient bed days within 12 months of the date of diagnosis. Brain tumour specific mortality and all-cause mortality were selected as the main outcomes of interest. While other outcomes were considered additional items to supplement these most clinically relevant outcomes.

Other demographic and clinical factors available for the descriptive analysis included age at diagnosis, sex, tumour location, tumour grade, route of presentation, Charlson comorbidity

index, deprivation level (SIMD quintile), urban/rural residence. Treatments received were recorded for the categories of surgery, radiotherapy, and use of temozolomide.

Statistical analysis

Analysis was stratified by tumour type. All procedures were repeated identically, limited to patients in each of three brain tumour categories. Tumours were grouped as Glioblastoma (GBM) and other grade 4 primary brain tumours (Grade 4 group), Grade 1-3 primary brain tumours (Grade 1-3 group), and Brain metastases. Results were also produced for the pooled sample including all three groups. The categories were chosen based on clinical relevance while still being sufficiently broad to allow meaningful results. This was conducted with the intention to explore the consistency of effects across these groups. Note that the metastases group included in the database was intentionally limited to exclude those with known active primary tumours at other sites (i.e. it includes those that presented with a brain tumour and subsequently discovered to be secondary to another site).

Mortality outcomes analysed by survival analysis were considered the primary outcomes. Hazard ratios were estimated for cancer-specific, overall mortality and tumour recurrence using Cox regression, including covariates to adjust estimates for potential confounding variables. For the additional outcomes of new or worsened neurological deficit, and 30-day mortality, odds ratios were estimated by logistic regression. Linear regression was used to estimate effects on the number of inpatient bed days. This was subject to first identifying if a linear relationship offered a reasonable approximation based on examining scatterplots and QQ plots.

The covariates included in all Cox, Logistic, or Linear regressions were age at diagnosis, sex, deprivation level (SIMD quintile), Charlson comorbidity index, and Glioblastoma (binary indicator, only applies for the pooled cohort). These variables were assessed to be potential confounders to the relationship between the exposures and outcomes. Clinical variables that we assessed to be mediators, downstream of time-to-treatment and tumour size, were excluded. This included features of presentation such as symptoms, as well as treatment intention and treatments received. Further potential confounders, such as molecular marker status were considered but not included due to limitations to data and sample size.

After examining the time-to-treatment data distributions and associations it was noted that interpretation was made challenging due to the presence of outliers. This caused estimated coefficients to be extremely small and in many cases indistinguishable from zero up to the fourth decimal place. To address this, a post-hoc analysis which stratified on time-to-treatment, using clinically relevant categories was added. The categories applied were <2 weeks, 2-6 weeks, 6-12 weeks and >12 weeks.

Complete case analysis was conducted therefore patients with missing data in relation to predictor, covariate or outcomes variables were excluded from the regression analysis.

Results

1196 of 1437 patients entered in the database were included in the study (Figure 1), comprising of 552 patients with Glioblastoma and other grade 4 tumours, 494 with grade 1-3 primary brain tumours and 150 with brain metastases. Descriptive statistics are displayed in Table 1. The mean age was 63. The mean tumour size was 40.6mm (SD: 17.5mm). Tumours were most commonly located in the frontal lobe (36.3%). Tumour size data was missing for 126 patients.

The most common route to diagnosis was via the emergency department (37.7%) and the majority of patients received surgical treatment (72%). In addition, 54% received radiotherapy treatment and 28% recorded use of temozolomide.

Survival varied by tumour type in the expected pattern. Median survival was 9 months for the Grade 4 group, 123.6 months for Grade 1-3 group and 7.6 months for metastases (Figure 2).

The time in clinical pathways patients followed from first presentation through referrals, diagnosis, and initial treatment are summarized in Table 1. The mean time from first presentation to treatment in the pooled sample was 161 days (median: 57 days) and was missing in 324 patients. Time interval varied by tumour type, for Grade 4 patients the mean was 75 days (median: 42 days), for non-GBM PBT patients it was 297 days (median: 116 days) and for patients with metastases 73 days (median: 40 days). Means being higher than medians, and large standard deviations (136-470 days), indicate strongly right skewed distributions in all categories. The difference in means between presentation to treatment and diagnosis to treatment indicates an average of around 40 days from presentation to diagnosis, with wide variation. High variance in these intervals reflects both variation in the duration until symptoms are recognised as a possible tumour, and variation in triage following diagnosis. For patients some with grade 1-3 primary brain tumours the variance is likely to also reflect watchful waiting strategies following diagnosis.

Associations between tumour size and patient outcomes are reported in Table 2. Tumour size (per cm larger) was associated with an increased risk of mortality from brain tumour. The direction of the association was observed to be consistent across tumour types (Figure SA1 & Table 2). The hazard ratio for tumour-specific mortality was 1.11 (95%CI:1.05 – 1.16) for grade 4 tumours, 1.24 (95%CI:1.12 – 1.37) for grade 1-3 tumours and 1.15 (95%CI:0.96 – 1.39) for metastases. Equivalent hazard ratios for all-cause mortality were 1.10 (1.05 – 1.16) for grade 4 tumours, 1.15 (1.05 – 1.25) for grade 1-3 tumours and 1.21 (1.02 – 1.42) for metastases. Associations in the pooled cohort are reported in the Supplementary Appendix (Table SA 1).

An association with increased risk of 30-day mortality was observed but this was only significant in the grade 4 group (OR: 1.50 95%CI: 1.09 - 2.08).

In total 445 recurrence events were observed (37% of the sample). There was evidence of reduced rate of recurrence in the grade 4 group (HR: 0.91, 95%CI: 0.84-0.98), and an increased rate of recurrence with increasing tumour size for grade 1-3 tumours (HR: 1.26, 95%CI:1.14-1.40).

New or worsened neurological deficit and longer total duration of inpatient stays were also associated with larger tumour sizes in some groups (Table 2). Compared to tumour-specific and all-cause mortality more variation and wider confidence intervals were observed across tumour types in relation to these outcomes. For grade 1-3 tumours larger size was associated with increased risk of new or worsened neurological deficit (OR: 1.27, 95%CI: 1.10-1.48) but this was not observed for grade 4 tumours (OR: 1.04, 95%CI: 0.92-1.17) or brain metastases (OR: 0.89, 95%CI: 0.56-1.38).

Equivalent unadjusted (univariate) results for all associations of tumour size with outcomes, both in the pooled sample and stratified by tumour type, are available in the Supplementary Appendix (Tables SA 2-5). Unadjusted results are very similar to the presented regression adjusted estimates with some small attenuation of effects following adjustment observed.

In the grade 1-3 group, increased time-to-treatment (per day, from first presentation) was associated with improved outcomes (Table 3) in relation to brain tumour mortality (HR:

0.9995, 95%CI:0.9988 - 1.0001), all-cause mortality (HR: 0.9987, 95%CI:0.9980 - 0.9995), and tumour recurrence (HR:0.9996, 95%CI:0.9992 - 1.0000). It should be noted that the combination of using hazard ratios for a per day change, and existence of long intervals, leads to very small coefficient values, making interpretation of clinical importance challenging. To illustrate the potential clinical relevance, the per day hazard ratio of brain tumour mortality of 0.9995 translates to a hazard ratio of 0.91 for a 180-day longer interval.

In the grade 4 and brain metastases groups, no clear association between time-to-treatment and better or worse patient outcomes was identified for any of the outcomes of interest.

The Supplementary Appendix provides results for unadjusted regressions (Tables SA 6,8,10,12), results for the alternative time-to-treatment definition (Tables SA 6-13), and results for the same analyses stratified by categories of time-to-treatment window (Tables SA 14-21). This sensitivity analysis found decreased risk of mortality with increased time-to-treatment in the 2-6 week and 6-12 week windows. There was little evidence of any association among those with greater than 12 weeks or less than 2 weeks duration of time-to-treatment.

Analysis stratified by time-to-treatment window categories (<2 weeks, 2-6 weeks, 6-12 weeks and >12 weeks) shows similar results to the base case analysis, improved outcomes with longer time windows, but with larger effect sizes observed in the 2-6 and 6-12 week groups (Tables SA 14-21).

Linear regression to estimate the relationship between time-to-treatment and inpatient length of stay was not applied because visual inspection of scatterplot and QQ plot did not suggest any approximately linear relationship was present.

Discussion

Causal effects of earlier or later diagnosis of brain tumours are difficult to identify because experimental methods cannot be used, and observational data are challenging to collect and interpret. To overcome this difficulty, we have investigated the relationship between tumour size and patient outcomes as it is believed to play an important role mediating the effect of earlier or delayed diagnosis. This approach is predicated on a simple chain of causation. Tumours grow over time, and for brain tumours, size of the primary tumour has a very direct relationship with the severity of disease as well as the likelihood of successful treatment. Larger tumours will affect healthy brain tissues to a greater degree, compromising function, while complete and partial resections will carry greater risks of surgical complications. Delays to diagnosis allow greater time for tumour growth.

A key limitation of this study comes from the need to create broad categories of tumour types; GBM and other grade 4 PBT, grade 1-3 PBT and brain metastases. The grade 1-3 PBT category in particular includes diverse tumour types with highly heterogeneous management. The grouping was clinically informed and reflects the grading system in use. We hypothesised that the relationship between changing tumour size and outcomes was nevertheless broadly similar across tumour types. Future studies should consider further dividing tumour subtypes into clinically relevant categories to the extent the data allows.

We have found evidence of the previously described 'waiting time paradox' in the relationship between time-to-treatment and patient outcomes for grade 1-3 primary tumours. In common with previous investigators, we believe this is due to differences between cases in observed and unobserved prognostic factors. Prognostic factors affect how clinicians and

patients assess the urgency of investigation and treatment. For example, in patients with similar symptoms, those whose symptoms progress more rapidly are likely to have diagnostic imaging earlier. Tumour growth and symptom progression is more likely with more aggressive tumours, which have a worse prognosis than lower grade tumours. Lower grade tumours grow more slowly, so symptoms will progress at a lower rate and diagnosis may therefore take longer, but these tumours have a better outcome. Hence, why for some patients a longer time to diagnosis is associated with a better outcome. This will also be impacted by greater use of observation in management of patients with better prognosis. Future studies could consider structured data collection of triage decisions and use of planned observation to better inform the effect of time-to-treatment.

We have observed several features that should increase our confidence in a causal interpretation of the impacts of tumour size on the patient outcomes of survival, brain tumour specific or all-cause, and inpatient length of stay. These include a strong association, clear temporality, a gradient of effect, consistency and clinical plausibility (23). Firstly, a strong association was observed in relation to cancer-specific mortality, all-cause mortality, and length of inpatient stay. Temporality is clear as tumour size is recorded at the time of radiological diagnosis. The expected gradient was observed in relation to length of inpatient stay. The observed associations were consistent across tumour types in relation to cancer-specific and all-cause survival and were consistent for inpatient stays except for brain metastases. Finally, because the mainstay of treatment is surgical resection and, *ceteris paribus*, surgery becomes more difficult (and urgent) with increased tumour size, the case for clinical plausibility is strong.

To illustrate the potential importance of the relationship between time-to-diagnosis, tumour size and outcomes consider as an example a patient with a GBM 60mm diameter at diagnosis (75th percentile in this patient population). Applying two alternative mean growth rate estimates derived by previous studies (24,25), this tumour would be expected to be 30.9-42.5mm if diagnosed 3 months earlier. The reduction in tumour size would imply a 17-26% decrease in the hazard of brain cancer mortality. In this example that would translate to approximately 37-42% rather than 30% of patients surviving at 1 year, and 5-7% rather than 3% of patients surviving at 3 years following diagnosis. Inpatient bed days would be reduced from approximately 34.7 to 30.8-32.4 days, saving approximately £1150-2000 in healthcare expenditure(26) (details of calculations for this worked example are provided in the Supplementary Appendix).

The impact of such earlier detection for the whole population of brain tumour patients, across tumour types and size at diagnosis, could be predicted in a future modelling study, providing input for additional analysis of the overall impact of early diagnosis. This would support economic evaluation of interventions targeting earlier diagnosis. In addition, future modelling can inform the impacts for even greater reductions in the time to diagnosis, for example from potential screening interventions.

An interesting further conclusion arising from this model of tumour growth and early detection is that because tumours grow approximately exponentially, the period of the last doubling in size prior to detection via symptoms is vitally important. This is when each day or week of earlier detection will have the largest effect on the tumour size at diagnosis. It follows that a few weeks can make a difference in the symptomatic setting while by the same logic it may also be true that a few weeks would be inconsequential in the setting of asymptomatic screening.

It is important to note the limitations imposed by the observational design of this study. Without having recourse to experimental data on delays to diagnosis and treatment, which

could only become available through a natural experiment, uncertainty will remain about whether the observed associations are causal. More definitive evidence may require interventional studies aimed at early detection with new technologies by either modification of diagnostic pathways or by screening. These studies would be necessarily large, expensive and lengthy. Further observational studies may be able to provide larger samples for more detailed subgroup analysis, or allow inclusion of additional covariates such as brain oedema and other clinical features that are potential confounders for the relationship between tumour size and outcomes.

Another limitation of this study is possible error in assigning the correct time of diagnosis or first presentation based on review of health care records. The true first presentation may not have been recognised or recorded within primary care. While we believe this does not have a major impact in these data if it were the case then this would have the effect of artificially shortening the observed intervals. Around ten percent of cases were excluded in the tumour size analysis due to missing data. We believe this is unlikely to cause substantial bias as the proportion is small and we do not believe missingness is related to the outcomes of interest. However, we cannot exclude the possibility.

Here, we have utilised a large brain tumour database linked to routine healthcare data to investigate the potential of earlier or delayed diagnosis to impact six important patient outcomes. Provided that we accept the logic that relates tumour size to earlier or later diagnosis, this study finds consistent evidence that delay does matter for brain tumour patients. New interventions leading to earlier diagnosis can hope to improve patient outcomes. Further studies, including prospective trials or real-world piloting, may be needed to confirm the impact of any specific early diagnosis intervention.

Author contributions: EG, MV, PH, and PB contributed to the conceptualization and study design. EG also contributed by writing of the original draft. PK and GT contributed to the data analysis. JC contributed to literature review. MB contributed through acquisition of funding. All authors contributed to data interpretation and writing through review and editing.

Declaration of interests: EG is a paid consultant of Dxcover Ltd. JC and AL are employees of Dxcover Ltd. and have stock options with the company. MB is a director and has a leadership role in Dxcover Ltd, with stock options with the company. LP and PB are paid consultants of Dxcover Ltd. PH, PK, GT and MH were supported in their work on this study from a contract between Dxcover Ltd and their employer (Edinburgh Innovations, University of Edinburgh).

Funding Statement: Dxcover Ltd provided funding for data access, analysis and writing. Dxcover employees were involved in the study design and the decision to publish the paper, as well as assisting with the writing of the report, but were not involved in the collection, analysis and interpretation of the data.

Acknowledgements: We would like to thank patients for providing access to their data, allowing this study to be completed.

Data Sharing: Under data governance rules these patient data can be accessed by researchers via application to Public Health Scotland (PHS) electronic Data Research and Innovation Service (eDRIS).

Ethics statement: Ethical approval for data access was granted the NHS Lothian DataLoch governance process that operates within NHS Lothian, with authority delegated from the NHS Lothian Caldicott Guardian, NHS Research Ethics Service and the NHS Lothian Research and Development department. The project objectives were assessed to be primarily for patient and public benefit. Patient-level data remained within the NHS Lothian secure environment. All analysis was undertaken by NHS Lothian staff. The data were de-identified prior to analysis to further protect subject privacy. Only aggregate reports were released from NHS Lothian subject to censoring for disclosure control. This study was conducted in accordance with the ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Pharmacoepidemiology Practices (GPPs) and applicable laws and regulations of the UK. This study did not receive a specific ethics approval reference number.

References

1. NHSD-NDRS. Routes to Diagnosis [Internet]. [cited 2025 Feb 3]. Routes to diagnosis dashboard. Available from: https://nhsd-ndrs.shinyapps.io/routes_to_diagnosis/
2. Ozawa M, Brennan PM, Zienius K, Kurian KM, Hollingworth W, Weller D, et al. Symptoms in primary care with time to diagnosis of brain tumours. *Fam Pract*. 2018;35(5):551–8. doi:10.1093/fampra/cmz139 PubMed PMID: 29420713.
3. The Brain Tumour Charity. Finding a better way? Improving the quality of life for people affected by brain tumours [Internet]. 2013 [cited 2023 Mar 2]. Available from: <https://www.basw.co.uk/resources/finding-better-way-improving-quality-life-people-affected-brain-tumours>
4. Lyratzopoulos G, Neal RD, Barbiere JM, Rubin GP, Abel GA. Variation in number of general practitioner consultations before hospital referral for cancer: findings from the

- 2010 National Cancer Patient Experience Survey in England. *Lancet Oncol.* 2012 Apr;13(4):353–65. doi:10.1016/S1470-2045(12)70041-4
5. Brennan PM, Butler HJ, Christie L, Hegarty MG, Jenkinson MD, Keerie C, et al. Early diagnosis of brain tumours using a novel spectroscopic liquid biopsy. *Brain Commun.* 2021 Apr 5;3(2). doi:10.1093/braincomms/fcab056
 6. Gray E, Butler HJ, Board R, Brennan PM, Chalmers AJ, Dawson T, et al. Health economic evaluation of a serum-based blood test for brain tumour diagnosis: Exploration of two clinical scenarios. *BMJ Open.* 2018 May 1;8(5). doi:10.1136/bmjopen-2017-017593
 7. Gray E, Cameron JM, Butler HJ, Jenkinson MD, Hegarty MG, Palmer DS, et al. Early economic evaluation to guide the development of a spectroscopic liquid biopsy for the detection of brain cancer. *Int J Technol Assess Health Care.* 2021;37(1). doi:10.1017/S0266462321000143 PubMed PMID: 33622443.
 8. Aggarwal A, Herz N, Campbell P, Arkush L, Short S, Rees J. Diagnostic delay and survival in high-grade gliomas - Evidence of the “waiting time paradox”? *Br J Neurosurg.* 2015;29(4):520–3. doi:10.3109/02688697.2015.1012050 PubMed PMID: 25738427.
 9. Kawauchi D, Ohno M, Miyakita Y, Takahashi M, Yanagisawa S, Omura T, et al. Early Diagnosis and Surgical Intervention Within 3 Weeks From Symptom Onset Are Associated With Prolonged Survival of Patients With Glioblastoma. *Neurosurgery.* 2022 Nov 1;91(5):741–8. doi:10.1227/neu.0000000000002096 PubMed PMID: 35951724.
 10. Do V, GebSKI V, Barton MB. The effect of waiting for radiotherapy for grade III/IV gliomas. *Radiotherapy and Oncology.* 2000;57(2):131–6. doi:10.1016/S0167-8140(00)00257-7
 11. Müller DMJ, De Swart ME, Ardon H, Barkhof F, Bello L, Berger MS, et al. Timing of glioblastoma surgery and patient outcomes: a multicenter cohort study. *Neurooncol Adv.* 2021;3(1):vdab053. doi:10.1093/noajnl/vdab053 PubMed PMID: 34056605.
 12. Aggarwal A, Herz N, Campbell P, Arkush L, Short S, Rees J. Diagnostic delay and survival in high-grade gliomas – evidence of the ‘waiting time paradox’? *Br J Neurosurg.* 2015 Jul 4;29(4):520–3. doi:10.3109/02688697.2015.1012050
 13. Kehoe K, Sivaguru H, Coulter I, Cowie C. Delay in the diagnosis of paediatric brain tumours: a systematic review. *Child’s Nervous System.* 2023 Aug 19;39(8):2053–63. doi:10.1007/s00381-023-06022-y
 14. Neal RD. Do diagnostic delays in cancer matter? *Br J Cancer.* 2009 Dec 3;101(S2):S9–12. doi:10.1038/sj.bjc.6605384
 15. Wangaryattawanich P, Hatami M, Wang J, Thomas G, Flanders A, Kirby J, et al. Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival. *Neuro Oncol.* 2015 Nov;17(11):1525–37. doi:10.1093/neuonc/nov117
 16. Leu S, Boulay JL, Thommen S, Bucher HC, Stippich C, Mariani L, et al. Preoperative Two-Dimensional Size of Glioblastoma is Associated with Patient Survival. *World Neurosurg.* 2018 Jul;115:e448–63. doi:10.1016/j.wneu.2018.04.067

17. Bruhn H, Tavelin B, Rosenlund L, Henriksson R. Do presenting symptoms predict treatment decisions and survival in glioblastoma? Real-world data from 1458 patients in the Swedish brain tumor registry. *Neurooncol Pract*. 2024 Sep 13;11(5):652–9. doi:10.1093/nop/npae036
18. Pignatti F, van den Bent M, Curran D, Debruyne C, Sylvester R, Therasse P, et al. Prognostic Factors for Survival in Adult Patients With Cerebral Low-Grade Glioma. *Journal of Clinical Oncology*. 2002 Apr 15;20(8):2076–84. doi:10.1200/JCO.2002.08.121
19. Chaichana KL, Chaichana KK, Olivi A, Weingart JD, Bennett R, Brem H, et al. Surgical outcomes for older patients with glioblastoma multiforme: preoperative factors associated with decreased survival. *J Neurosurg*. 2011 Mar;114(3):587–94. doi:10.3171/2010.8.JNS1081
20. Greenland S, Robins JM. Identifiability, Exchangeability, and Epidemiological Confounding. *Int J Epidemiol*. 1986;15(3):413–9. doi:10.1093/ije/15.3.413
21. Leppert J, Ditz C, Matschke J, Matone MV, Kuppler P, Hillbricht C, et al. Preoperative Tumor Growth Rate Does Not Predict Overall or Progression-free Survival in Patients With Glioblastoma. *Anticancer Res*. 2024 Nov 1;44(11):5043–9. doi:10.21873/anticancer.17328 PubMed PMID: 39477314.
22. Weller D, Vedsted P, Rubin G, Walter FM, Emery J, Scott S, et al. The Aarhus statement: Improving design and reporting of studies on early cancer diagnosis. *British Journal of Cancer*. 2012. p. 1262–7. doi:10.1038/bjc.2012.68 PubMed PMID: 22415239.
23. Hill AB. The Environment and Disease: Association or Causation? *Proc R Soc Med*. 1965 May;58(5):295–300. doi:10.1177/003591576505800503
24. Swanson KR, Alvord EC, Murray JD. Virtual brain tumours (gliomas) enhance the reality of medical imaging and highlight inadequacies of current therapy. *Br J Cancer*. 2002 Jan 25;86(1):14–8. doi:10.1038/sj.bjc.6600021
25. Feucht D, Haas P, Skardelly M, Behling F, Rieger D, Bombach P, et al. Preoperative growth dynamics of untreated glioblastoma: Description of an exponential growth type, correlating factors, and association with postoperative survival. *Neurooncol Adv*. 2024 Jan 1;6(1). doi:10.1093/noajnl/vdae053
26. NHS Scotland. Scottish Costs Book, R040 [Internet]. 2024 Feb [cited 2025 Mar 10]. Available from: <https://publichealthscotland.scot/healthcare-system/system-monitoring-accountability-and-quality-of-care/finance-within-the-nhs/costs-book/costs-book-publication/>

Figure Legends

Figure 1 – Participant flow, subgroups and exclusions

Figure 2 Kaplan-Meier survival analysis of overall survival, tumour type subgroups and pooled cohort. Patients still alive at the latest passive follow-up were right-censored. Numbers at risk displayed below.

Glioblastoma is an aggressive brain tumor. The authors of this study wanted to determine how the time between finding a brain tumor and starting treatment, as well as tumor size when found, related to survival and other patient health measures. To do this, they reviewed records from 1,196 patients with brain tumors and examined how treatment timing and tumor size were related to survival, nerve-related problems, tumor return, hospital stay, and death within 30 days. Their results showed that larger tumors were linked to a higher risk of death and longer hospital stays, and that a 1 cm increase in glioblastoma tumor size was associated with about a 11% higher risk of death.

ACCEPTED MANUSCRIPT

Table 1 - Descriptive Statistics

	GBM + Grade 4 non-GBM primary tumour (N=552)	Grade 1-3 non-GBM primary tumour (N=494)	Brain metastases (n = 150)	All (n=1196)
Age at diagnosis				
Mean (SD)	62.0 (13.2)	55.2 (17.2)	64.0 (11.4)	59.4 (15.2)
Median (Q1, Q3)	64.0 (54.0, 71.0)	54.0 (43.0, 69.0)	65.0 (56.2, 72.0)	61.0 (50.0, 70.0)
Sex				
Female	226 (40.9%)	275 (55.7%)	75 (50.0%)	576 (48.2%)
Male	326 (59.1%)	219 (44.3%)	75 (50.0%)	620 (51.8%)
Primary cancer subtype				
Glioblastoma	459 (83.2%)	0 (0.0%)	0 (0.0%)	459 (38.4%)
Other Glioma	83 (15.0%)	210 (42.5%)	0 (0.0%)	293 (24.5%)
Meningioma	<10 (<1.8%)	>168 (>34%)	0 (0.0%)	178 (14.9%)
Other primary brain cancer	<10 (<1.8%)	>98 (>20%)	0 (0.0%)	116 (9.7%)
Metastasis	0 (0.0%)	0 (0.0%)	150 (100.0%)	150 (12.5%)
Tumour size at diagnosis (cm)¹				
Mean (SD)	4.6 (1.7)	3.8 (1.8)	3.0 (1.2)	4.1 (1.8)
Median (Q1, Q3)	4.5 (3.4, 5.7)	3.7 (2.4, 5.0)	3.0 (2.2, 3.7)	4.0 (2.8, 5.3)
Number Missing	>40	>75	<10	126
Tumour size category (cm)				
< 3	81 (15.9%)	143 (<40%)	69 (<48%)	293 (27.4%)
3 – 5.9	315 (61.8%)	213 (≥50%)	73 (≥50%)	601 (56.2%)
≥ 6	114 (22.4%)	>50 (>10%)	<10 (<2%)	176 (16.4%)
Number Missing	>40	>75	<10	126
Tumour location				
Frontal	196 (36.8%)	161 (37.5%)	46 (30.9%)	403 (36.3%)
Temporal	125 (23.5%)	74 (17.2%)	11 (7.4%)	210 (18.9%)
Parietal	88 (16.5%)	56 (13.1%)	20 (13.4%)	164 (14.8%)
Occipital	≥10 (≥1.8%)	≥10 (≥2%)	<10 (<6.6%)	36 (3.2%)
Cerebellar	<10 (<1.8%)	≥10 (≥2%)	33 (22.1%)	64 (5.8%)
Brainstem	<10 (<1.8%)	33 (7.7%)	<10 (<6.6%)	37 (3.3%)
Multiple	103 (19.3%)	62 (14.5%)	32 (21.5%)	197 (17.7%)
Number Missing	≥10	65	<10	85
Tumour grade				
1	<10 (<1.9%)	143 (37.1%)	<10 (<20%)	149 (20.1%)
2	<10 (<1.9%)	87 (22.6%)	<10 (<20%)	90 (12.1%)
3	<10 (<1.9%)	62 (16.1%)	<10 (<20%)	67 (9.0%)
4	413 (98.1%)	0 (0.0%)	24 (80.0%)	437 (58.8%)
Number Missing	131	202	120	453
Presentation				
Primary care	22 (6.2%)	40 (10.3%)	14 (11.1%)	76 (8.7%)

Secondary care	182 (51.3%)	224 (57.4%)	61 (48.4%)	467 (53.6%)
Emergency	151 (42.5%)	126 (32.3%)	51 (40.5%)	328 (37.7%)
Number Missing	197	104	24	325
Treatment received (Surgery, Radiotherapy and/or Temozolomide)				
Yes	446 (80.8%)	362 (73.3%)	103 (68.7%)	911 (76.2%)
No	106 (19.2%)	132 (26.7%)	47 (31.3%)	285 (23.8%)
Surgery				
Yes	425 (77.0%)	346 (70.0%)	87 (58.0%)	858 (71.7%)
No	127 (23.0%)	148 (30.0%)	63 (42.0%)	338 (28.3%)
Radiotherapy				
Yes	390 (70.7%)	188 (38.1%)	66 (44.0%)	644 (53.8%)
No	162 (29.3%)	306 (61.9%)	84 (56.0%)	552 (46.2%)
Temozolomide				
Yes	249 (45.1%)	64 (13.0%)	17 (11.3%)	330 (27.6%)
No	303 (54.9%)	430 (87.0%)	133 (88.7%)	866 (72.4%)
Comorbidity (CCI)*				
0	477 (86.4%)	436 (88.3%)	96 (64.0%)	1009 (84.4%)
1-2	59 (10.7%)	46 (9.3%)	18 (12.0%)	123 (10.3%)
3 or more	16 (2.9%)	12 (2.4%)	36 (24.0%)	64 (5.4%)
Deprivation score (SIMD)**				
1 (Most deprived)	>60 (>10%)	<70 (<14%)	<20 (<13%)	>140 (>11%)
2	125 (22.7%)	110 (22.5%)	29 (19.5%)	264 (22.2%)
3	>100 (>18%)	<100 (<20%)	<40 (<27%)	>240 (>20%)
4	130 (23.6%)	107 (21.9%)	28 (18.8%)	265 (22.3%)
5 (Least deprived)	124 (22.5%)	114 (23.3%)	35 (23.5%)	273 (23.0%)
Number Missing	<10	<10	<10	<10
Urban/Rural residence				
Urban	399 (76.7%)	347 (82.0%)	108 (80.0%)	854 (79.2%)
Rural	121 (23.3%)	76 (18.0%)	27 (20.0%)	224 (20.8%)
Number Missing	32	71	15	118
Healthcare Resource Use				
Outpatient visits				
Mean (SD)	4.6 (3.3)	5.2 (3.7)	6.1 (5.0)	5.0 (3.7)
Median (Q1, Q3)	4.0 (2.0, 6.0)	5.0 (2.0, 7.0)	5.0 (2.0, 9.0)	4.0 (2.0, 7.0)
Number Missing	84	48	23	155
Inpatient visits				
Mean (SD)	5.3 (3.1)	4.8 (3.1)	6.0 (3.8)	5.2 (3.2)
Median (Q1, Q3)	5.0 (3.0, 7.0)	4.0 (3.0, 6.0)	5.0 (3.0, 7.0)	4.0 (3.0, 7.0)
Number Missing	33	101	11	145
Total length of stay (days)				

Mean (SD)	31.8 (32.8)	28.3 (39.4)	34.5 (32.4)	30.8 (35.4)
Median (Q1, Q3)	20.0 (7.5, 47.0)	13.0 (6.0, 36.0)	24.0 (13.0, 48.0)	18.0 (7.0, 44.0)
Number Missing	33	101	11	145
Average length of stay (days)				
Mean (SD)	6.3 (6.3)	5.7 (6.6)	6.7 (7.2)	6.1 (6.5)
Median (Q1, Q3)	4.1 (2.0, 8.7)	3.0 (1.8, 7.2)	4.7 (2.4, 7.5)	3.8 (2.0, 7.9)
Number Missing	33	101	11	145
Time from radiological diagnosis to first treatment (days)				
Mean (SD)	30.0 (75.2)	173.5 (395.3)	41.5 (123.8)	88.3 (267.0)
Median (Q1, Q3)	17.0 (10.0, 27.0)	43.5 (15.0, 126.8)	19.0 (12.0, 36.0)	21.0 (12.0, 49.0)
Number Missing	106	132	47	285
Time from first presentation to treatment (days)				
Mean (SD)	75.0 (135.6)	297.0 (469.6)	73.5 (133.2)	161.5 (329.9)
Median (Q1, Q3)	41.5 (25.0, 77.8)	116.0 (48.8, 338.8)	41.0 (27.0, 70.0)	57.0 (30.0, 132.5)
Number Missing	118	154	53	325
Time from primary care referral to treatment (days)				
Mean (SD)	37.0 (60.5)	202.2 (362.4)	35.4 (44.6)	105.1 (250.4)
Median (Q1, Q3)	19.0 (11.0, 40.5)	65.0 (21.8, 205.2)	22.0 (14.0, 41.2)	28.0 (13.5, 82.5)
Number Missing	257	230	70	557

Note: Small numbers are censored due to information governance requirements of the source data.

1 The assessments of tumour size recorded were based on standard care as reported by consultant radiologist. For tumours with contrast enhancement, including all GBM, Meningioma and metastases the measurement is from the T1-weighted post gadolinium imaging, including the maximum area confined by the peripheral contrast enhancement. For low grade gliomas it is T2-weighted hyperintense region.


Table 2 – Tumour Size & Patient Outcomes Association (multivariable adjusted)


Main Outcomes	GBM + Grade 4 non-GBM primary tumour (N=508)	Grade 1-3 non-GBM primary tumour (N=413)	Brain metastases (n = 143)
<i>Hazard Ratio, Odds Ratio, Coefficient (95% Confidence Interval)</i>			
Brain cancer mortality	1.11 (1.05 – 1.16)	1.24 (1.12 – 1.37)	1.15 (0.96 – 1.39)
All-cause mortality	1.10 (1.05 – 1.16)	1.15 (1.05 – 1.25)	1.21 (1.02 – 1.42)
Additional outcomes			
30-day mortality	1.50 (1.09 – 2.08)	0.87 (0.53 – 1.32)	1.46 (0.83 – 2.70)
Recurrence	0.91 (0.84 – 0.98)	1.26 (1.14 – 1.40)	1.05 (0.81 – 1.35)
New or worsened neurological deficit	1.04 (0.92 – 1.17)	1.27 (1.10 – 1.48)	0.89 (0.56 – 1.38)
Inpatient bed days, 12 months following diagnosis*	1.31 (-0.45 - 3.08) [Obs. = 480]	2.20 (-0.01 – 4.40) [Obs. = 332]	1.09 (-3.68 - 5.86) [Obs. = 132]

*Reduced number of observations due to missing outcome data, number of observations given in square brackets

Table 3 – Time From First Presentation To Treatment & Patient Outcomes Association

Main Outcomes	GBM + Grade 4 non-GBM primary tumour (N=432)	Grade 1-3 non-GBM primary tumour (N=338)	Brain metastases (N = 96)
<i>Hazard Ratio, Odds Ratio, Coefficient (95% Confidence Interval)</i>			
Brain cancer mortality	0.9996 (0.9989 - 1.0004)	0.9995 (0.9988 – 1.0001)	0.9973 (0.9920 - 1.0026)
All-cause mortality	0.9998 (0.9991 - 1.0005)	0.9987 (0.9980 - 0.9995)	0.9993 (0.9975 - 1.0012)
Additional Outcomes			
30-day mortality	0.8671 (0.5168 – 1.0029)	1.0000 (0 – 3.075 x 10 ³⁵)	0.8951 (0.4792 – 1.0162)
Recurrence	0.9996 (0.9985 - 1.0007)	0.9996 (0.9992 - 1.0000)	0.9979 (0.9934 - 1.0023)
New or worsened neurological deficit	0.9994 (0.9973 - 1.0009)	1.0001 (0.9996 - 1.0006)	0.9993 (0.9921 - 1.0031)
Inpatient bed days, 12 months following diagnosis	n/a	n/a	n/a





Sample		Time (years)	0	1	2	3	4	5
Pooled	N risk		1196	674	513	437	343	292
	Surv.		1	0.564	0.429	0.371	0.332	0.313
GBM + Grade 4 Non GBM	N risk		552	211	100	52	23	15
	Surv.		1	0.382	0.179	0.103	0.062	0.047
Other Non GBM primary	N risk		494	409	385	364	307	265
	Surv.		1	0.828	0.779	0.737	0.693	0.662
Metastasis	N risk		150	54	28	21	13	12
	Surv.		1	0.360	0.187	0.146	0.113	0.104